Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Insider David Krempa Sells 6,800 Shares

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 6,800 shares of the firm’s stock in a transaction on Friday, June 13th. The shares were sold at an average price of $14.77, for a total transaction of $100,436.00. Following the completion of the transaction, the insider now directly owns 622,869 shares in the company, valued at approximately $9,199,775.13. This represents a 1.08% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

David Krempa also recently made the following trade(s):

• On Monday, June 16th, David Krempa sold 10,223 shares of Eton Pharmaceuticals stock. The shares were sold at an average price of $14.73, for a total value of $150,584.79.
• On Thursday, June 12th, David Krempa sold 16,977 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $14.92, for a total transaction of $253,296.84.

Eton Pharmaceuticals Trading Down 0.9%

NASDAQ:ETON traded down $0.13 during mid-day trading on Monday, reaching $14.17. 324,095 shares of the stock were exchanged, compared to its average volume of 224,421. Eton Pharmaceuticals, Inc. has a 1-year low of $3.18 and a 1-year high of $21.48. The firm has a market capitalization of $380.01 million, a PE ratio of -64.41 and a beta of 1.28. The business has a fifty day moving average price of $16.54 and a 200 day moving average price of $15.05.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Tuesday, May 13th. The company reported $0.07 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.02). The company had revenue of $17.28 million during the quarter, compared to analysts’ expectations of $14.33 million. Eton Pharmaceuticals had a negative return on equity of 36.29% and a negative net margin of 15.81%. On average, sell-side analysts forecast that Eton Pharmaceuticals, Inc. will post -0.14 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Two Sigma Advisers LP acquired a new position in Eton Pharmaceuticals in the 4th quarter valued at approximately $662,000. Millennium Management LLC bought a new stake in Eton Pharmaceuticals during the fourth quarter worth approximately $1,850,000. Balyasny Asset Management L.P. bought a new stake in shares of Eton Pharmaceuticals during the 4th quarter worth $158,000. Two Sigma Investments LP bought a new position in shares of Eton Pharmaceuticals in the fourth quarter worth about $1,498,000. Finally, Jane Street Group LLC grew its stake in shares of Eton Pharmaceuticals by 328.6% in the fourth quarter. Jane Street Group LLC now owns 64,323 shares of the company’s stock worth $857,000 after acquiring an additional 49,317 shares during the last quarter. 27.86% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $35.00 target price (up from $33.00) on shares of Eton Pharmaceuticals in a research note on Thursday, May 29th. B. Riley restated a “buy” rating and set a $26.00 price objective (up previously from $24.00) on shares of Eton Pharmaceuticals in a research report on Friday, May 16th. Finally, Craig Hallum lifted their price target on Eton Pharmaceuticals from $26.00 to $28.00 and gave the company a “buy” rating in a report on Wednesday, May 14th.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.